For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Alnylam Pharmaceuticals Inc (ALNY) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score -12 (−100…+100 Quality+Value blend) · Quality 32 · Value -48 · Sentiment -45 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Alnylam Pharmaceuticals Inc
ALNY NASDAQAlnylam Pharmaceuticals Inc is a global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of therapeutics based on RNA interference technology. The company focuses on treating genetically defined and other hard-to-treat diseases by silencing specific genes implicated in disease pathways. Its commercial portfolio includes approved RNAi medicines for rare conditions such as hereditary transthyretin-mediated amyloidosis and primary hyperoxaluria type 1, alongside therapies targeting acute hepatic porphyria and other metabolic and cardiovascular disorders. Alnylam also maintains a broad clinical pipeline in cardiometabolic disease, neuroscience, and hematology, aiming to address areas of high unmet medical need with targeted RNAi-based approaches. The company works across the United States, Europe, and other international markets, supported by strategic collaborations with healthcare providers, commercial partners, and technology firms. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals today plays a central role in bringing RNAi therapeutics into routine medical practice and is widely regarded as a pioneer in this modality.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 2.33
Total Equity: $789.18M
Shares: 134,684,000
Total Debt: $0.00
Cash: $1.66B
EBITDA: $557.24M
Total Debt: $0.00
Cash: $1.66B
Revenue: $3.71B
Revenue: $3.71B
Revenue: $3.71B
Total Equity: $789.18M
Tax Rate: 2.9%
Equity: $789.18M
Total Debt: $0.00
Cash: $1.66B
Current Liabilities: $1.47B
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $789.18M
Shares: 134,684,000
Shares: 134,684,000
CapEx: -$58.70M
Shares: 134,684,000
Stock Price: $228.65
Net Income: $313.75M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 15, 2026 11:20am (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $844.3M | $1.0B | $1.8B | $2.2B | $3.7B |
| Cost of Revenue | $115.0M | $140.2M | $268.2M | $306.5M | $677.2M |
| Gross Profit | $729.3M | $897.2M | $1.6B | $1.9B | $3.0B |
| Operating Expenses | $1.4B | $1.7B | $1.8B | $2.1B | $2.5B |
| Operating Income | -$708.7M | -$785.1M | -$282.2M | -$176.9M | $501.6M |
| Net Income | -$852.8M | -$1.1B | -$440.2M | -$278.2M | $313.7M |
| EBITDA | -$661.1M | -$740.6M | -$228.1M | -$120.2M | $557.2M |
| EPS | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.39 |
| EPS (Diluted) | $-7.20 | $-9.30 | $-3.52 | $-2.18 | $2.33 |
Balance Sheet (Annual)
Last updated: Aug 15, 2026 11:03am (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $820.0M | $866.4M | $812.7M | $966.4M | $1.7B |
| Total Current Assets | $2.8B | $2.7B | $3.0B | $3.3B | $4.1B |
| Total Assets | $3.6B | $3.5B | $3.8B | $4.2B | $5.0B |
| Current Liabilities | $695.7M | $767.9M | $967.8M | $1.2B | $1.5B |
| Long-Term Debt | — | — | — | — | — |
| Total Liabilities | $3.1B | $3.7B | $4.1B | $4.2B | $4.2B |
| Total Equity | $588.2M | -$158.2M | -$220.6M | $67.1M | $789.2M |
| Retained Earnings | -$5.4B | -$6.6B | -$7.0B | -$7.3B | -$6.7B |
Cash Flow (Annual)
Last updated: Aug 15, 2026 11:20am (8d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$641.7M | -$541.3M | $104.2M | -$8.3M | $524.1M |
| Capital Expenditure | -$76.4M | -$72.1M | -$62.2M | -$34.3M | -$58.7M |
| Free Cash Flow | -$718.1M | -$613.3M | $41.9M | -$42.6M | $465.4M |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | $0 | -$762.1M | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $323.1M | $46.4M | -$53.7M | $153.8M | $690.2M |
Growth Trends (YoY %)
Last updated: Aug 15, 2026 11:20am (8d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +22.9% | +76.2% | +23.0% | +65.2% |
| Gross Profit Growth | +23.0% | +73.9% | +24.5% | +56.4% |
| Operating Income Growth | -10.8% | +64.1% | +37.3% | +383.6% |
| Net Income Growth | -32.6% | +61.1% | +36.8% | +212.8% |
| EBITDA Growth | -12.0% | +69.2% | +47.3% | +563.5% |
Deep Analysis
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-15AI's biggest economic contact point is diagnosis, not drug design: AI-ECG/echo/imaging algorithms are converting undiagnosed cardiac amyloidosis into identified, treatable patients, and Alnylam is the incumbent with an approved ATTR-CM label and treatment-center relationships to absorb that flow at high price per patient-year.
AI compresses the cost and time of generating and optimizing oligonucleotide candidates and of designing trials, which erodes the 20-year head start embedded in Alnylam's siRNA/GalNAc know-how and accelerates competing modalities — including one-time gene editing that would replace a recurring q3-month annuity with a single payment.
Whether the AI-enlarged diagnosed patient pool grows Alnylam's treated base faster than AI-accelerated competing modalities take share. Observables: new ATTR-CM diagnosis/initiation rates disclosed with Amvuttra volumes versus editing and small-molecule stabilizer Phase 3 readouts.
GalNAc-conjugate delivery chemistry with more than a decade of human dosing and safety data, approved labels in specific genetic indications, sterile injectable manufacturing at scale, and payer/center-of-excellence relationships in rare disease.
AI Lens thesis
Alnylam monetizes a treated patient per year, not seats, hours, or information processing, so the deflationary channel that guts software and services barely touches its revenue line; AI reaches it through three narrow doors — (1) cheaper target validation, sequence design and trial operations, which lowers cost per program at exactly the moment the company crosses into operating profit (13.5% OpM on $3.71B, FCF $465M), (2) AI diagnostics that mechanically expand the addressable diagnosed population in ATTR, the single largest driver of the current inflection, and (3) entrant compression, where cheap design tools let competitors reach the same validated genetic targets and let editing platforms iterate faster toward a curative one-shot product that would destroy chronic-dosing economics; the net is favorable because the scarce assets AI cannot copy — approvals, delivery chemistry validated in humans, manufacturing, payer access — sit above the layer AI commoditizes.
What the market may be underestimating
Upside AI screening of existing echo/ECG archives is a demand-side, zero-marketing-cost patient-finding engine for an already-approved product — the rare case where cheap intelligence directly expands units sold rather than deflating price.
Downside Alnylam's revenue is an annuity on chronic silencing; AI most accelerates the modality class (editing, durable stabilizers) whose value proposition is ending the annuity, and payers will underwrite that switch enthusiastically at rare-disease price points.
Outcome range spread 41
Growth Outlook
Analyzed 2026-08-17 16:30The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw trajectory here is genuinely impressive and I want to lead with it before getting to the caveats: quarterly revenue went from $500.9M (Q3 2024) to $773.7M (Q2 2025) to $1.25B (Q3 2025) to $1.10B (Q4 2025) to $1.29B (Q2 2026). That's not linear growth — that's a step-change, consistent with Amvuttra's ATTR-CM label expansion (approved March 2025) hitting the P&L. The 65% YoY revenue growth and the swing from -$111.6M net income (Q3 2024) to +$251.1M (Q3 2025) and +$164.5M (Q2 2026) is a legitimate profitability inflection, not accounting cosmetics. Annual FCF at $465M on $3.71B revenue is real cash. So the "high-growth profitable" archetype is correct, and the pre-flight "pre-profit-platform" label is stale — Alnylam is profitable now, at scale, on a franchise that just doubled its addressable population.
Where I diverge from the synthesis is the "fully_priced / composite $178" verdict. On my back-of-envelope: run-rating Q2 2026 revenue of $1.29B gives ~$5.2B, and if ATTR-CM penetration is early (it is — vutrisiran's ATTR-CM launch is <18 months old against a ~150K US patient pool competing with tafamidis), $7-8B revenue in 2027-28 is plausible without pipeline heroics. At 20% net margins that's $1.4-1.6B of earnings, putting forward P/E at 19-22x on a platform still growing 30%+. That does not look "fully priced" — it looks reasonable for a de-risked biotech with a validated modality. The synthesis's $178 fair value implicitly assumes revenue growth decelerates fast; I don't see the evidence for that in the quarterly cadence. The signal-adjusted $240 is closer to my read.
The contrarian case worth taking seriously isn't the tired "RNAi has disappointed for 15 years" narrative — that's a bear story from 2018, not 2026, and the ATTR franchise settles it. The real contrarian argument is competitive: BridgeBio's acoramidis (Attruby) launched late 2024 with a differentiated stabilizer mechanism and is taking share in ATTR-CM; Ionis's eplontersen is a direct RNAi/ASO competitor in ATTR-PN; and the cardiometabolic pipeline (zilebesiran for hypertension) faces a wall of GLP-1s and cheap generics. If ATTR-CM share caps at 30-35% instead of the 50%+ implicit in bull models, revenue tops out closer to $5.5B and the 98x trailing P/E starts to bite. The other real risk: the Q2 2026 margin (12.7%) is *lower* than Q3 2025 (20.1%) and Q4 2025 (14%). That's not a trend yet, but it's worth watching — SG&A ramp for cardiometabolic trials could compress margins meaningfully before pipeline revenue arrives.
Data quality caveats: the "2026-03-31: rev —" line is a hole in the file that matters; without Q1 2026 I can't tell if the Q2 sequential looks like acceleration or catch-up. The P/B of 39 is a non-signal for a biotech (intangibles-driven), correctly flagged. Insider activity is neutral-to-slightly-negative (small sales after option exercises, standard comp behavior — not a signal). The "Poor Cash Flow Quality" flag contradicts the reported $465M FCF and $524M OCF and I'd discount it — the flag is probably triggered by the recent transition from losses, not underlying accrual games. Where I partially agree with synthesis: valuation IS fragile in the sense that a Phase 3 miss on zilebesiran or ALN-KHK, or a competitive setback in ATTR, would compress the multiple hard. This is not a "back up the truck" name at $228 — it's a name where the fundamentals are catching up to the multiple and where the next 4-6 quarters of ATTR-CM uptake data are the whole ballgame.
Net: I dissent from "fully_priced." The quarterly acceleration is more powerful than the composite DCF captures, and the pre-flight/synthesis framing underweights that Q3-Q4 2025 already proved the profitability model. Fair value is closer to $250-270 on my numbers, with meaningful downside to $170 if ATTR-CM disappoints. Starter position defensible; not table-pounding because competitive dynamics in ATTR are genuinely fluid and the pipeline optionality is not free.
GPT Reading
What jumps out is not the RNAi story but the speed of the financial turn. Alnylam went from $2.25B of revenue and a $278M net loss in 2024 to $3.71B of revenue and $314M of net income in 2025, a 65% top-line jump with operating margin swinging from -7.9% to +13.5%. That is a real inflection, not accounting noise alone, because operating cash flow also moved positive to $524M and free cash flow to $465M. Quarterly data show the same break: revenue ran roughly $500M-$770M through 2024 and 1H25, then stepped up to $1.25B in 3Q25, $1.10B in 4Q25, and $1.29B in 2Q26, with net margins now consistently positive in the low-teens to 20% range after years of red ink. A biotech that has actually crossed from platform promise into self-funded commercial execution deserves a premium multiple.
But the stock already has one. At a $30.6B market cap, investors are paying about 8.2x trailing sales, nearly 98x trailing earnings, and over 50x EV/EBITDA for a company whose latest full-year net margin is still only 8.5%. Even if I annualize the strongest recent revenue run-rate using the visible quarters, the business may now be capable of something like $4.8B-$5.0B in revenue, which brings the sales multiple down somewhat, but it does not make the earnings multiple comfortable unless margins keep expanding materially. This is the central issue: the income statement has improved dramatically, but valuation assumes that 2025 was not a one-off step-up and that 2026-2028 will convert much more of each incremental dollar into profit. That can happen in orphan biotech once the cost base is leveraged, yet the current price leaves limited room for any wobble in launch trajectory, pricing, or pipeline timing.
I also do not buy the most bearish framing that cash flow quality is poor. The provided data show the opposite directionally: free cash flow of $465M against net income of $314M in 2025 is healthy, not suspect, and cash of $1.66B with no debt listed gives Alnylam unusual strategic flexibility for biotech. The ugly 39x P/B is a balance-sheet artifact of only $789M of equity, not a useful sign of excess by itself. Where I am cautious is that profitability is still young and probably lumpy. The quarter ending 2025-06-30 still lost $72M on $774M of revenue before the step-change in the back half, and biotech revenue can be distorted by milestone, collaboration, or stocking dynamics. So while the business is clearly better than the old “pre-profit platform” label, I think the market has jumped quickly from proving viability to pricing durable large-cap biopharma economics.
The strongest pushback to my skepticism is straightforward: if 2025 was the first full year of scale and 2026 is simply the first normalized year of earnings power, trailing PE is almost irrelevant. A company growing revenue 40%+ over several years, holding gross margin above 80%, and now dropping hundreds of millions into operating and free cash flow can look optically expensive right before margins inflect hard. If the current quarterly run-rate near $1.1B-$1.3B is sustainable, annual revenue could exceed $5B sooner than the market once expected, and a move from 8.5% net margin to 20%+ would make today’s valuation far less demanding. On that bull case, $30B for the category leader in a validated modality with no balance-sheet stress is not crazy at all. I weigh that argument less heavily because the stock is being underwritten on future mix, penetration, and pipeline execution that the disclosed numbers alone do not yet prove.
What would change my mind is surprisingly specific. If the next two reported quarters show revenue holding above $1.1B each without a large collapse in net margin—say, sustained 15%+ net margins and operating cash flow continuing to outrun earnings—then I would be more willing to value Alnylam on forward earnings power rather than trailing optics, and $230 would look reasonable to cheap. Conversely, if revenue slips back toward the $700M-$900M zone or margins retreat to breakeven, then the 2025-2026 surge will look more episodic than structural and the multiple should compress sharply. For now I see a genuinely transformed company, but one whose transformation is already substantially capitalized in the stock.
Grok Reading
Alnylam’s numbers describe a genuine commercial inflection, not a narrative overlay. Revenue scaled from $844M in 2021 to $2.25B in 2024 to $3.71B in 2025—a 65% year-over-year jump and a 42.5% multi-year CAGR—while the P&L flipped from an operating loss of $177M and net loss of $278M in 2024 to operating income of $502M and net income of $314M in 2025. Free cash flow of $465M against only $59M of capex is the cleaner signal: cash conversion already exceeds reported earnings, which directly contradicts the “poor cash flow quality” flag in the secondary models. Quarterly run-rate has stabilized in the $1.1–1.3B band (Q3 2025 $1.25B, Q4 $1.10B, Q2 2026 $1.29B), implying a mid-$5B annualized pace if growth simply holds, not accelerates. Gross margin of 82% and a debt-free balance sheet with $1.66B cash give real operating leverage; the 98x trailing P/E and 8.3x sales multiple are being earned against a franchise that only just crossed the profitability threshold, not against a mature earner. Book value of $789M and the 39x P/B are artifacts of accumulated losses and intangibles—they are not useful anchors.
The story the raw data tell is platform validation with commercial proof, not pure optionality. Operating margin expanded from deeply negative to 13.5% in a single year; ROE printed 40% on the thin equity base. That is the math of a rare-disease commercial engine (ATTR and adjacent labels) still early in penetration, not of a pre-revenue science project. At $30.6B enterprise value on $3.71B sales and ~$465M FCF, the market is paying roughly 66x current free cash flow and 7.6x EV/revenue—expensive in absolute terms, but consistent with a high-teens-to-mid-twenties forward multiple if revenue compounds into the $5–7B zone and margins keep climbing toward 20%+. The signal-adjusted fair value near $241 versus $229 is directionally right: the stock is not in bubble territory relative to the growth already delivered.
The strongest case against this read is that almost nothing in the multiple is paid for by today’s earnings power alone. A 98x P/E, 51x EV/EBITDA, and an implied need for something like $10B-plus long-term revenue scale mean the stock is a pipeline and label-expansion vehicle dressed in commercial clothes. The thesis evaluation’s slight bear tilt (−6) is fair on that point: competitive RNAi, antisense, CRISPR, and cardiometabolic incumbents can compress both pricing and share, and one or two Phase 3 misses would collapse the duration the multiple requires. ROIC still prints negative (−56%), which—even if partly a lagged capital base—reminds you that cumulative economic profit has not yet been earned. Valuation synthesis correctly flags fragility: few downside scenarios support $229 if growth decelerates toward 20% or margins stall in the low teens. Insider flow is noise (option exercises and related sales), not confirmation.
I would flip to decisively bearish on a clear competitive share loss in the ATTR franchise, a material Phase 3 failure in a larger-indication program, or two consecutive quarters of sub-20% revenue growth with operating margin compression. I would flip more bullish on sustained quarterly revenue above $1.4B with operating margins pushing through 20%, or a clean late-stage win that de-risks a multi-billion cardiometabolic label and forces consensus toward $6B-plus revenue inside three years.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Revenue scaled from $844M (2021) to $3.71B (2025), a ~4.4x lift in four years with gross margins holding in the low-to-mid 80s. Operating margin inflected from -83.9% to +13.5% and net income turned positive at $313.7M in 2025 after cumulative losses exceeding $2.7B in 2021-2024. FCF flipped to a solid $465.4M, meaning the company now self-funds without recourse to capital markets. Altman Z of 4.21 puts it in the safe zone and net cash of $1.66B provides real, if not enormous, cushion (5.4% of market cap).
Verify before trusting this (6)
- Composition of 2025 revenue jump — is Amvuttra/TTR expansion the driver and how concentrated is it by product/geography?
- Whether OCF/NI 0.54x reflects working capital build (receivables from launch) or lower-quality accruals
- Sustainability of the ~82% GM level versus 86% historical - mix or pricing?
- Royalty/collaboration revenue vs product revenue split and durability
- Detail on SBC grant policy and whether buybacks are contemplated now that FCF is positive
- Pipeline read-through beyond ATTR franchise (competitive threat from BridgeBio, Ionis, Pfizer)
The composite fair value of $178 implies ~22% downside, while the signal-adjusted FV of $241 implies ~5% upside - bracketing today's $228.65 price. The methods disagree wildly: DCF says $134, EPV floor says $14 (essentially zero steady-state earnings power - a runaway floor reflecting that GAAP profits just turned positive in 2025), and anchored P/E says $295. The EPV number should be largely ignored; it captures the fact that trailing earnings are tiny, not that the business is worth nothing. Stripping that out, the honest range is roughly $134 (DCF) to $295 (peer multiple), centering near the current quote. What is priced in: continued rare-disease franchise growth plus a credible option on the cardiometabolic pivot. That is not heroic, but it is not discounted either - the market already gives Alnylam credit for the 2025 inflection ($3.7B revenue, 13.5% op margin, $465M FCF). To justify meaningful upside from here you need the cardiometabolic expansion to hit, not just the base to compound. Quality is solid (score 32) but with ~3% annual dilution and only one year of GAAP profit, I am not willing to pay a fortress multiple. Net: fair, not cheap.
Verify before trusting this (4)
- 2026 revenue guidance and mix between rare-disease franchises and cardiometabolic programs
- Operating margin trajectory - is 13.5% a floor or a peak tied to a specific product cycle
- Share count guidance and SBC as % of revenue
- Any Phase 3 readouts in cardiometabolic that could re-rate the deserved multiple
The macro tape is mildly risk-on with VIX at 14 and indices near highs, but with a 0.28 beta ALNY barely participates in that lift. What actually moves this name is the platform narrative and single-catalyst news flow, and both currently lean negative. The July 30 -28% air pocket on a guidance cut and worries about Amvuttra second-line demand normalizing is the dominant recent sentiment event and still colors positioning. Even with strong 3-year momentum (42% CAGR, +65% trailing), a single-day 28% drawdown resets the tape psychology and puts every subsequent print under a suspicious lens. The platform-monopoly narrative has only moderate intensity and moderate durability with a medium cult - not the kind of true-believer base that absorbs a guide-down without flinching. The cardiometabolic pivot is the bull case buyers need, but competing modalities (GLP-1, CRISPR, antisense) are eating oxygen in the story wars, and 15 years of 'next big thing' fatigue caps how much narrative premium the tape will re-extend before a clean Phase 3 win.
Verify before trusting this (4)
- Next Amvuttra quarterly script trend - stabilization would break the demand-normalization bear framing
- Any Phase 3 readout in cardiometabolic that would re-arm the platform narrative
- Analyst target revisions post the July guide-down - stabilizing or still cutting
- Whether the stock reclaims the pre-gap level or the July high acts as resistance
Alnylam monetizes a treated patient per year, not seats, hours, or information processing, so the deflationary channel that guts software and services barely touches its revenue line; AI reaches it through three narrow doors — (1) cheaper target validation, sequence design and trial operations, which lowers cost per program at exactly the moment the company crosses into operating profit (13.5% OpM on $3.71B, FCF $465M), (2) AI diagnostics that mechanically expand the addressable diagnosed population in ATTR, the single largest driver of the current inflection, and (3) entrant compression, where cheap design tools let competitors reach the same validated genetic targets and let editing platforms iterate faster toward a curative one-shot product that would destroy chronic-dosing economics; the net is favorable because the scarce assets AI cannot copy — approvals, delivery chemistry validated in humans, manufacturing, payer access — sit above the layer AI commoditizes.
None surfaced.
Verify before trusting this (8)
- Net price per patient trend
- Persistence and discontinuation rates
- One-time therapy pricing precedents
- Gene-editing ATTR Phase 3 durability data
- Oral TTR competitor filings
- Dosing-interval extension progress
- Third-party GalNAc-style delivery entrants
- IP expiry and litigation on conjugates
The world is moving toward earlier, imaging-and-genetics-based diagnosis of infiltrative cardiomyopathy, which mechanically enlarges Alnylam's market every year independent of its own commercial execution. RNAi has moved past platform-risk into execution-risk: the question is no longer whether gene silencing works in humans but how much of a cardiology market a quarterly injectable can hold against oral stabilizers. Macro headwinds (10y at 4.63) matter to how such duration is discounted but barely touch prescription volumes for a symptomatic, mortality-reducing therapy. Broader drug-pricing policy is the real world-level risk: a rare-disease price point stretched across a cardiology-sized population is exactly the profile policymakers target.
Prediction unavailable. valuation-synthesis has no result for ALNY — the prediction needs its fair-value anchors.